bluebird gains on beta thalassemia data

bluebird bio Inc. (NASDAQ:BLUE) jumped $8.37 (32%) to $34.46 on Monday after reporting that two patients with beta thalassemia major who received autologous hematopoietic stem cell transplantations (HSCTs) with bluebird's LentiGlobin BB305 achieved blood transfusion independence within two weeks of transplant. The patients were the first in the open-label, French Phase I/II HGB-205 trial, which is enrolling up to seven patients with beta thalassemia major or severe sickle cell disease. Data were presented at the European Hematology Association meeting in Milan. ...